Vera Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities
Vera Therapeutics, Inc. (VERA) reported Increase (Decrease) in Accrued Liabilities of $2.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-10
- Vera Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $2.51M, a 69.04% decline year-over-year.
- Vera Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$437.00K.
- Vera Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $7.21M.
- Vera Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $3.92M, a 51.46% decline year-over-year.
- Vera Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $14.44M, a 100.92% increase from fiscal 2024.
- Vera Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $7.19M.
- Vera Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was -$2.21M, a 131.48% decline from fiscal 2022.
- Vera Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $7.04M, a 30.47% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $2.07M 10-Q · filed 2026-08-10 | $9.28M derived: sum of 3 quarters · filed 2026-08-10 | $13.19M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$437.00K 10-Q · filed 2026-05-07 | $6.77M derived: sum of 2 quarters · filed 2026-05-07 | $10.69M derived: sum of 3 quarters · filed 2026-05-07 | $18.79M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $7.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.12M derived: sum of 2 quarters · filed 2026-02-26 | $19.22M derived: sum of 3 quarters · filed 2026-08-10 | $14.44M 10-K · filed 2026-02-26 |
| 2025-09-30 | $3.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $12.02M derived: sum of 2 quarters · filed 2026-08-10 | $7.23M 10-Q · filed 2025-11-05 | $3.47M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $8.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $3.32M 10-Q · filed 2026-08-10 | -$448.00K derived: sum of 3 quarters · filed 2026-08-10 | $7.62M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$4.78M 10-Q · filed 2026-05-07 | -$8.55M derived: sum of 2 quarters · filed 2026-05-07 | -$483.00K derived: sum of 3 quarters · filed 2026-05-07 | $4.10M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$3.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.30M derived: sum of 2 quarters · filed 2026-02-26 | $8.88M derived: sum of 3 quarters · filed 2026-02-26 | $7.19M 10-K · filed 2026-02-26 |
| 2024-09-30 | $8.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $12.64M derived: sum of 2 quarters · filed 2025-11-05 | $10.96M 10-Q · filed 2025-11-05 | $9.90M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $4.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $2.89M 10-Q · filed 2025-08-05 | $1.83M derived: sum of 3 quarters · filed 2026-02-26 | $643.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$1.69M 10-Q · filed 2025-05-07 | -$2.74M derived: sum of 2 quarters · filed 2026-02-26 | -$3.94M derived: sum of 3 quarters · filed 2026-02-26 | -$8.54M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.25M derived: sum of 2 quarters · filed 2026-02-26 | -$6.85M derived: sum of 3 quarters · filed 2026-02-26 | -$2.21M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$5.80M derived: sum of 2 quarters · filed 2024-11-07 | -$1.16M 10-Q · filed 2024-11-07 | $3.58M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$4.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $31.00K 10-Q · filed 2024-08-08 | $4.78M derived: sum of 3 quarters · filed 2024-08-08 | $5.25M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $4.64M 10-Q · filed 2024-05-10 | $9.38M derived: sum of 2 quarters · filed 2024-05-10 | $9.86M derived: sum of 3 quarters · filed 2024-05-10 | $7.45M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $4.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $5.22M derived: sum of 2 quarters · filed 2024-03-27 | $2.81M derived: sum of 3 quarters · filed 2024-03-27 | $7.04M 10-K · filed 2024-03-27 |
| 2022-09-30 | $474.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$1.93M derived: sum of 2 quarters · filed 2023-11-09 | $2.29M 10-Q · filed 2023-11-09 | $5.51M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$2.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.82M 10-Q · filed 2023-08-10 | $5.03M derived: sum of 3 quarters · filed 2023-08-10 | $6.06M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $4.22M 10-Q · filed 2023-05-11 | $7.44M derived: sum of 2 quarters · filed 2023-05-11 | $8.46M derived: sum of 3 quarters · filed 2023-05-11 | $8.55M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $3.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $4.24M derived: sum of 2 quarters · filed 2023-03-28 | $4.32M derived: sum of 3 quarters · filed 2023-03-28 | $5.39M 10-K · filed 2023-03-28 |
| 2021-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.11M derived: sum of 2 quarters · filed 2022-11-09 | $2.18M 10-Q · filed 2022-11-09 | $2.02M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $84.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $1.15M 10-Q · filed 2022-08-10 | $999.00K derived: sum of 3 quarters · filed 2022-08-10 | $1.09M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $1.07M 10-Q · filed 2022-05-16 | $915.00K derived: sum of 2 quarters · filed 2022-05-16 | $1.01M derived: sum of 3 quarters · filed 2022-05-16 | $1.06M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$154.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$63.00K derived: sum of 2 quarters · filed 2022-03-28 | -$4.00K derived: sum of 3 quarters · filed 2022-03-28 | $110.00K 10-K · filed 2022-03-28 |
| 2020-09-30 | $91.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $150.00K derived: sum of 2 quarters · filed 2021-11-10 | $264.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $59.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $173.00K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $114.00K 10-Q · filed 2021-06-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |